Incyte Corp (NASDAQ:INCY)

87.80
Delayed Data
As of Feb 23
 +2.61 / +3.06%
Today’s Change
80.85
Today|||52-Week Range
153.15
-7.30%
Year-to-Date
Zacks.com featured highlights include: Incyte, Altice USA, Archrock, Live Nation and...
Feb 21 / Zacks.com - Paid Partner Content
Incyte (INCY) Beats on Sales in Q4
Feb 15 / Zacks.com - Paid Partner Content
Get Rid of 5 Toxic Stocks or Sell Short for Profit
Feb 19 / Zacks.com - Paid Partner Content
Why Incyte (INCY) Might Surprise This Earnings Season
Feb 14 / Zacks.com - Paid Partner Content
Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales
Feb 15 / Zacks.com - Paid Partner Content
Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?
Feb 12 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close85.19
Today’s open85.43
Day’s range84.88 - 88.02
Volume1,460,410
Average volume (3 months)1,712,018
Market cap$18.0B
Data as of 4:00pm ET, 02/23/2018

Growth & Valuation

Earnings growth (last year)-383.33%
Earnings growth (this year)+82.65%
Earnings growth (next 5 years)+57.90%
Revenue growth (last year)+38.93%
P/E ratioNM
Price/Sales12.61
Price/Book11.04

Competitors

 Today’s
change
Today’s
% change
ZTSZoetis Inc+2.03+2.51%
ALXNAlexion Pharmaceutic...+4.34+3.79%
BAXBaxter International...+0.93+1.38%
MYLMylan NV+0.17+0.41%
Data as of 4:03pm ET, 02/23/2018

Financials

Next reporting dateMay 3, 2018
EPS forecast (this quarter)-$0.48
Annual revenue (last year)$1.5B
Annual profit (last year)-$313.1M
Net profit margin-20.38%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts